Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

RSS icon
artificial intelligence AI deep learning

AI model uses DNA to predict AFib, heart failure

Scientists were able to identify a total of 21 genes linked to cardiovascular conditions such as AFib and heart failure.

ElectroDucer Sleeve PCI TAVR EuroIntervention

New direct wire pacing device shows potential during PCI and TAVR, first-in-human study finds

Early evidence suggests the Electroducer Sleeve is safe and effective among patients presenting for certain interventional procedures. 

Tim Attebery, DSc, MBA, the CEO of Cardiovascular Associates of America and former CEO of the American College of Cardiology (ACC)

Q&A: Tim Attebery on why private equity-backed management companies are investing in cardiology

The CEO of Cardiovascular Associates of America, and former CEO of the American College of Cardiology, shared his perspective on the rise of private equity investments in cardiology. 

Bertram Pitt, MD, a professor of medicine emeritus at the University of Michigan School of Medicine, explains the role of sodium–glucose co-transporter-2 (SGLT-2) inhibitors for heart failure (HF). Initially developed to treat diabetes, these drugs have been shown to improve HF outcomes in HF in several large, randomized trials over the past few years, including SOLOIST-WHF, DAPA-HF, EMPEROR-Preserved, and the DELIVER trials. The positive results earned their inclusion in the 2022 AHA/ACC/HFSA Guideline for

What clinical research tells us about sotagliflozin and heart failure

Some SGLT2 inhibitors have been linked to significant improvements in HF outcomes, but what about sotagliflozin? We spoke with Bertram Pitt, MD, to learn more.

Thumbnail

Vericiguat consistently linked to positive outcomes, limited side effects among heart failure patients

Reviewing data from several studies, researchers wrote that vericiguat (Verquvo) could potentially "become a breakthrough in the treatment of heart failure." 

Thumbnail

High-risk patients ineligible for bypass surgery see ‘profound improvements’ after PCI

High-risk patients with complex CAD who are ineligible for CABG can still see substantial benefits from PCI.

Thumbnail

New guideline on mechanical circulatory support tackles device selection, ethical dilemmas and more

The Heart Failure Society of America and International Society for Heart and Lung Transplantation worked together on the document, hoping their recommendations serve as a "critical roadmap" for clinicians. 

Thumbnail

More than a feeling? Social isolation, loneliness linked to a higher heart failure risk

A new study published in JACC: Heart Failure offers more evidence that a patient's feelings can strongly influence their risk of poor cardiovascular health. 

Displaying 177 - 184 of 1270

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.